![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MEDAG |
Gene summary for MEDAG |
![]() |
Gene information | Species | Human | Gene symbol | MEDAG | Gene ID | 84935 |
Gene name | mesenteric estrogen dependent adipogenesis | |
Gene Alias | AWMS3 | |
Cytomap | 13q12.3 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q5VYS4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84935 | MEDAG | C51 | Human | Oral cavity | OSCC | 2.24e-06 | 5.09e-01 | 0.2674 |
84935 | MEDAG | NEOLP-1 | Human | Oral cavity | NEOLP | 1.91e-05 | 4.19e-01 | -0.0194 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
GO:00455983 | Oral cavity | OSCC | regulation of fat cell differentiation | 77/7305 | 139/18723 | 6.36e-05 | 5.18e-04 | 77 |
GO:00456006 | Oral cavity | OSCC | positive regulation of fat cell differentiation | 41/7305 | 66/18723 | 1.20e-04 | 8.60e-04 | 41 |
GO:004560022 | Oral cavity | NEOLP | positive regulation of fat cell differentiation | 24/2005 | 66/18723 | 3.20e-08 | 1.35e-06 | 24 |
GO:004559821 | Oral cavity | NEOLP | regulation of fat cell differentiation | 37/2005 | 139/18723 | 1.12e-07 | 4.05e-06 | 37 |
GO:004544422 | Oral cavity | NEOLP | fat cell differentiation | 50/2005 | 229/18723 | 6.79e-07 | 1.93e-05 | 50 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEDAG | SNV | Missense_Mutation | c.370N>G | p.Lys124Glu | p.K124E | Q5VYS4 | protein_coding | tolerated(0.44) | benign(0) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
MEDAG | SNV | Missense_Mutation | rs758793268 | c.796N>T | p.Asp266Tyr | p.D266Y | Q5VYS4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
MEDAG | SNV | Missense_Mutation | c.628N>T | p.Leu210Phe | p.L210F | Q5VYS4 | protein_coding | tolerated(0.41) | benign(0.018) | TCGA-BG-A0RY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MEDAG | SNV | Missense_Mutation | c.799N>T | p.Asp267Tyr | p.D267Y | Q5VYS4 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.804) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MEDAG | SNV | Missense_Mutation | novel | c.693G>T | p.Lys231Asn | p.K231N | Q5VYS4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEDAG | SNV | Missense_Mutation | novel | c.376N>T | p.Asp126Tyr | p.D126Y | Q5VYS4 | protein_coding | tolerated(0.16) | possibly_damaging(0.789) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEDAG | SNV | Missense_Mutation | c.525N>T | p.Lys175Asn | p.K175N | Q5VYS4 | protein_coding | deleterious(0.03) | benign(0.095) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
MEDAG | SNV | Missense_Mutation | novel | c.860N>C | p.Leu287Ser | p.L287S | Q5VYS4 | protein_coding | deleterious_low_confidence(0.01) | benign(0.38) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
MEDAG | deletion | Frame_Shift_Del | novel | c.539delC | p.Pro180GlnfsTer11 | p.P180Qfs*11 | Q5VYS4 | protein_coding | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MEDAG | insertion | Frame_Shift_Ins | rs753872842 | c.718_719insA | p.Met242AsnfsTer3 | p.M242Nfs*3 | Q5VYS4 | protein_coding | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |